Adcendo ApS Unveils Promising Phase 1 Results for ADCE-D01 in Advanced Soft Tissue Sarcoma at EORTC-NCI-AACR 2026
Adcendo ApS Presents Groundbreaking Phase 1 Clinical Trial Results for ADCE-D01
On November 19, 2026, Adcendo ApS, a biotechnology firm focused on antibody-drug conjugates (ADCs), reported promising initial findings from its ongoing Phase 1 clinical trial of ADCE-D01. This first-in-class ADC targets the uPARAP receptor in patients suffering from advanced soft tissue sarcoma (STS). The findings were presented during a late-breaking session at the 38th EORTC-NCI-AACR Symposium held in Barcelona, Spain.
Key Findings from the Trial
The trial, known as ADCElerate1, involved patients with advanced STS who had already undergone several lines of treatment. Remarkably, the study revealed a significant 30% objective response rate and an 85% disease control rate among the evaluated participants. These results provide a hope for many who suffer from this challenging condition, especially since traditional second-line treatments only yield response rates between 4-10%.
Prof. Dr. Patrick Schöffski, a key investigator in the trial from University Hospitals Leuven, praised the findings, stating that ADCE-D01 could represent a groundbreaking advancement for patients who have run out of standard therapeutic options.